Evidence map›Paper›PMID 38439632›Full record

ArticleDalton transactions (Cambridge, England : 2003)2024

Seraj O Alzahrani, Graeme McRobbie, Abid Khan, Thomas D'huys, Tom Van Loy, Ashlie N Walker, Isaline Renard, Timothy J Hubin, Dominique Schols, Benjamin P Burke and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Seraj O AlzahraniCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.
Graeme McRobbieCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.
Abid KhanCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.
Thomas D'huysKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Tom Van LoyKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Ashlie N WalkerDepartment of Chemistry and Physics, Southwestern Oklahoma State University, Weatherford, OK 73096, USA.
Isaline RenardCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.ORCID http://orcid.org/0000-0003-4121-143X
Timothy J HubinDepartment of Chemistry and Physics, Southwestern Oklahoma State University, Weatherford, OK 73096, USA.ORCID http://orcid.org/0000-0003-2277-1191
Dominique ScholsKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Benjamin P BurkeCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.
Stephen J ArchibaldCentre for Biomedicine and Positron Emission Tomography Research Centre, Hull York Medical School and University of Hull, Cottingham Road, Hull, HU6 7RX, UK. stephen.archibald@kcl.ac.uk.ORCID http://orcid.org/0000-0001-7581-8817
University of Hull · GBRega Institute for Medical Research · BESouthwestern Oklahoma State University · USSt Thomas' Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chemokine receptor CXCR4 is implicated in multiple diseases including inflammatory disorders, cancer growth and metastasis, and HIV/AIDS. CXCR4 targeting has been evaluated in treating cancer metastasis and therapy resistance. Cyclam derivatives, most notably AMD3100 (Plerixafor™), are a common motif in small molecule CXCR4 antagonists. However, AMD3100 has not been shown to be effective in cancer treatment as an individual agent. Configurational restriction and transition metal complex formation increases receptor binding affinity and residence time. In the present study, we have synthesized novel

Indexed as

Coordination ComplexesCyclamsHeterocyclic CompoundsBenzylaminesReceptors, CXCR4BenzylaminesCoordination ComplexescyclamCyclamsHeterocyclic CompoundsplerixaforReceptors, CXCR4

Identifiers

PMID38439632
PMCPMC10949960
OpenAlexW4392191774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.